The deep-rooted changes of present times make forecasting the future of any enterprise (including biomedical research in organ replacement) ambitious, if not utopian. Forecasting is actually becoming quite an industry. A new science (called Futurology) is emerging. Futurologists neither discover, nor invent the future. They envisage possible, or futurable, futures, using neither myth nor fantasy, but Scientific Research and High Technology. They proclaim not prophecies, but "scenarios".
After 25 years' experience in reading the changes in the dialysis "scenario", the new frontiers (whether clinical, economic or social) seem indeed all too shifting, too "futurable". There is a need to ground our thinking on organ replacement in the levelheaded original policy of "patient first, and then technology", resisting the tyranny of escalating technology with its law of supply and demand.
Many important lessons for the future of dialysis can be drawn from the dialysis patient: the demonstration that dialysis has risen from a technological discipline to a multidisciplinary science; the discrepancy between theoretical and applied knowledge; the current cultural clash between Society and Science. The former demands a technological product, needless of the research behind the product, and science so far has obeyed the laws of the market continuing to spawn technologies that differ in form, but not in content. As a direct result, dialysis has witnessed a progressive inbreeding of cognitive science; a recurrence of the drawbacks of applied technology; a satisfactory survival rate; but a general disappointing of all other expectations (a five-timeshigher hospitalization rate than normal; a 60% unemployment rate, and a 40% disability rate). Thus, for a less "futurabie" future of dialysis -the real new frontiers of the future -the lessons from the patient are the finest basis of discussion for how to get back to the patient. Three main headings suggest themselves: 1) Research Allocation; 2) Applied Technology; 3) Bioethics.
Research allocation
The need for further scientific research, aimed at improving knowledge of how renal damage sets in and progresses, is undoubtedly established. Over 60% of renal diseases, in fact, evolve over varying periods of time towards uremia. This is due to inadequate diagnosis and/or inadequacy of the present treatment approach.
One of the main problems never previously discussed is where the resources for scientific research should be properly allocated.
In view of the proposed future changes to the National Health System, the Academic Institutions, the Research Centres (public and private) of the University and Hospital Departments (sometimes envisaged as "productive businesses" and not as simple places of health care), one may well wonder which of such institutions will be given priority for scientific dialysis research (cognitive and applied), and which will stand as Teaching Schools or Faculties.
No specific references exist in print. But there do exist some general prospective analyses of the future of Academic Medical Centres under health care reform (1) which may reasonably cover dialysis-related problems as well. It is rightly emphasised how the expected and admitted competition among the various Medical Centres is to serve as a stimulus to research. Excellence in research, with all attendant health and economic benefits, will ensure the survival of such Centres, above all those which respond to the wishes of society in terms of restricting health care spending, improving the efficiency and the quality of the work they do, and providing evidence that they have done so (1) .
Leaders of Academic Medical Institutions believe that teaching, research and patient care are interdependent functions that are best performed together (2) , but this credo is difficult to prove. In dialysis, as in all other fields, Academic Medical Centres for research have certain clear advantages: excellence of their faculty and staff members; experience in educa-tion, biomedical investigations and dealing with complex clinical problems; and their unique position at the boundary between the laboratory and the clinical setting (1). On the other hand, they have structural and attitudinal disadvantages (size, entrenched bureaucracies, rivalries among specialities etc.) that impede their potential ability to achieve breakthroughs in efficiency (3) .
Clearly, in organ replacement therapy, and dialysis in particular:
1) regardless of the details of any plan that is adopted, the customers of research activity (government, business, the public) will require that both "Centres" and "Providers" be self-accountable in all their spending.
2) Scientific progress is an iterative not a linear process and cognitive and applied Science benefits greatly when inventor and user can continuously interact (4) .
It is likely that in future it will be Programmes more than Institutions as such which qualify for economic backing (public and private) in support of basic scientific research for both production and teaching. The Centres will have to give guarantees of technological reliability, of streamlining in bureaucracy, and of recognised quality of their academic teaching standards. Mixed Centres, therefore, where the public and the private sectors integrate in mutual respect and in the interest of their institutional goals, seem the first target to aim for.
Applied technology
After years on dialysis, yesterday's "rehabilitatee" is now a mere "survivor". The complexity of the alterations (cardiovascular, gastrointestinal, bone disease, malnutrition) makes it hard to see how such patients manage to survive. Behind these clinical and biological alterations, there are 3 basic causes (Tab. II).
The first cause is the so-called "artificial kidney". This actually works as a glomerulus and as such may only offset part of the uremic alterations (5, 6) . Even the most sophisticated technology "per se" will never replace the homeostatic, regulatory and endocrine functions of the kidney (7, 8) .
To offset this kind of persisting uremic change there is a need to combine integrating biological components to supplement the intrinsic short-60 comings of the techno-device, making it more similar physiologically to the human kidney, and hence lowering the unphysiology of treatment and improving patient pathobiology (9) .
Biological integration via technology may now be rationally contemplated, since tissue engineering is a rapidly developing field in biotechnology. The hope is to produce biotechnological implantable devices. The biological component may derive from cells codified for specific tubular functions (10), as well as renal endocrine functions, as foreseen for the so-called Bionic Kidney (11) , where the miniaturized technological and biological components monitor each other in an electronically triggered feed-back mechanism. For the moment, all researches into implantable bioartificial kidneys remain at the experimental stage. What has actually been done is the fruit of a few people's ideas constantly recycled by others, without being enriched or stimulated by anything new.
While the implantable bioartificial kidney as a way to enhancing clinical dialysis results remains, for the moment, at the "futurable" phase of a hope, there do already exist in dialysis certain biotechnological programmes (12) , based on the same assumptions: to supplement, modulate and biologize artificial replacement therapy and improve the clinical results of dialysis.
Some examples: use of products obtained from recombinant DNA (for instance, EPO); specific sorbents; biosensors modulating the feed-back of dialysis operative parameters; cells capable of producing biologically active substances (such as pancreas betacells) or releasing products to stimulate the biology component of the bio-device, etc.
The second cause of dialysis patient morbidity (above all malnutrition and cardiovascular disease) is due to belated dialysis therapy, after over-protracted periods of Low Protein Diet (LPD). The malnutrition that invariably ensues is never thereafter reversed by dialysis, whatever the supplementary treatment (diet, aminoacids, etc). Malnutrition in dialysis should not be treated but prevented. Many years ago (5, 6) we began recommending Early Dialysis (ED), a schedule aimed at avoiding malnutrition, keeping the protein intake constantly adequate and varying dialysis rhythm (5-7) according to the reduction in creatinine.
Between Early and Late dialysis, the differences concern: survival (at 5, 10, 20 years); lower risk of infection and cardiovascular disease over the first 5-10 years (13). One hopes there will be wider circulation of these ideas in future and more general clinical use of these results.
The third cause of clinical and biological alterations in the long-term dialysis patient lies in the treatment itself. As is well known, some alterations set in passively and automatically (osmotic imbalance, plastic particles depositing in various tissues, etc.); others follow an active course in biological reaction to the stress of dialysis. Above all the bioincompatibility of dialysis materials is thought to play the main role in this biological trade-off which the patient pays for surviving: it occurs through activation of the kinine system which, in turn, affects a number of biological systems (immunological, neuro-endocrinal, hematological, etc.). However, the real role played by this alleged biological activation in the final clinical outcome (survival and morbidity) is not fully known. What we do know is that, for all their possible differences in terms of biological reaction and functional efficiency, there are no significant differences in the clinical outcome between cellulosic and synthetic membranes in controlled long-term trials (14) .
Nonetheless, since signs of intradialytic biological activation exist (15, 16) ; since treatment, and hence activation, is repetitive; and since predominant among the bioactivations is immunological stimulation, which seems in the long run to bring on a kind of dialysis rejection (12) , it is to be hoped that futu re attem pts will continue at deantigenizing dialysis membranes. An experiment is already being made with "ionic plasma" or plasma "pre-coated" with an autologous protein layer. Future research (Tab. III), finally, will have to focus on the materials issue (membranes and circuits) to make them truly bio-materials in the full etymological sense. The problem is how to insert in the dialysis material various biotechnological products (ligands, enzymes, codified cells) geared towards set specific biological tasks. More accurate studies on the molecular basis of materials are indispensable in the next step of "anchoring" them biologically. A lot of research is already going on here, but in extra-dialysis fields.
Bioethics
The literature lacks all specific reference to the bioethical repercussions that the constant technological enhancing of dialysis may bring about. Some thoughts on medicine in general do exist, and provide a good basis for reference and reflection (Tab. IV). 1) When dialysis gets "exasperated" in time, can it go on forming part of the patient's so-called "living will"? This comprises what the still living patient makes known about his own wishes concerning, among other things, the escalation of therapy. What if survival goes on improving, and the patient gets worse and worse? That is one possible outcome.
2) Can we foresee some kind of genetic map (above all at the outset, before treatment) to help us forecast who will respond to long-term treatment best, thus guiding us in decisions for which today we are prepared neither spiritually nor intellectually?
3) By the same token: will an employer be able to require that his aspiring (dialysed) employees undergo clinical testing to see if they are a "good investment" from the health standpoint?
4) The challenge to devise new strategies for distributing resources is bound to intensify (a demand for unlimited forms of treatment on a limited health budget). 5) Can we foresee an increase in law-suits seeking compensation for long-term clinical and biological anomalies in the dialysis patient, beyond what was spelt out to him at the beginning of treatment?
6) The problem of welfare assistance to the vulnerable (AIDS victims, for elderly, the mentally disturbed, etc.) will return to the fore. Already in some countries, for questions of interest, ideology and distribution of resources, the general health cover to such categories has fallen to an unthinkable level.
These are a few of the problems (typical of the developed world) which will emerge in dialysis in the future, to find their place on the "agenda" of bioethics. They should be mentioned not so much for reasons of philosophical relevance, as for the repercussions which the medical world may actually be facing in a near future.
CONCLUSIONS
These, in a nutshell, are the 3 main lines for predicting how the frontiers of dialysis will shift in future. In each case our doubts lead us to start from the patient and return to the patient, thus involving all those bound up in the problem: patients, doctors, research centres, public institutions, private companies, and so on.
Though purely predictory, these doubts should not be dismissed out of hand. To go on doubting may be the spice of life. For among other things, it helps us to foresee and prevent, and it is well known that an ounce of prevention outweighs a pound of cures.
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